Li Kang Biomedical Co., Ltd.

TPEX:6242 Voorraadrapport

Marktkapitalisatie: NT$1.4b

Li Kang Biomedical Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Li Kang Biomedical has been growing earnings at an average annual rate of 13.4%, while the Personal Products industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 9.6% per year. Li Kang Biomedical's return on equity is 10.3%, and it has net margins of 14.7%.

Belangrijke informatie

13.4%

Groei van de winst

13.0%

Groei van de winst per aandeel

Personal Products Groei van de industrie13.9%
Inkomstengroei9.6%
Rendement op eigen vermogen10.3%
Nettomarge14.7%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Li Kang Biomedical (GTSM:6242) Has Some Way To Go To Become A Multi-Bagger

Apr 19
Li Kang Biomedical (GTSM:6242) Has Some Way To Go To Become A Multi-Bagger

Is Li Kang Biomedical Co., Ltd. (GTSM:6242) A Smart Choice For Dividend Investors?

Mar 09
Is Li Kang Biomedical Co., Ltd. (GTSM:6242) A Smart Choice For Dividend Investors?

Li Kang Biomedical Co., Ltd.'s (GTSM:6242) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Feb 09
Li Kang Biomedical Co., Ltd.'s (GTSM:6242) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

The Trends At Li Kang Biomedical (GTSM:6242) That You Should Know About

Jan 19
The Trends At Li Kang Biomedical (GTSM:6242) That You Should Know About

We Think Li Kang Biomedical (GTSM:6242) Can Stay On Top Of Its Debt

Dec 29
We Think Li Kang Biomedical (GTSM:6242) Can Stay On Top Of Its Debt

Three Things You Should Check Before Buying Li Kang Biomedical Co., Ltd. (GTSM:6242) For Its Dividend

Dec 08
Three Things You Should Check Before Buying Li Kang Biomedical Co., Ltd. (GTSM:6242) For Its Dividend

Opbrengsten en kosten

Hoe Li Kang Biomedical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

TPEX:6242 Opbrengsten, kosten en inkomsten (TWD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 24572842930
31 Mar 24597952950
31 Dec 236291112930
30 Sep 236531162920
30 Jun 237121293000
31 Mar 237391262680
31 Dec 226841122510
30 Sep 22622982360
30 Jun 22498732040
31 Mar 22395552090
31 Dec 21387512070
30 Sep 21419612150
30 Jun 21514792400
31 Mar 21482752270
31 Dec 20457692200
30 Sep 20429602140
30 Jun 20371462040
31 Mar 20436592300
31 Dec 19483722450
30 Sep 19468702390
30 Jun 19477722420
31 Mar 19506752520
31 Dec 18496772480
30 Sep 18517862560
30 Jun 185181372600
31 Mar 184981392520
31 Dec 174961342530
30 Sep 174851272500
30 Jun 17472722420
31 Mar 17458662390
31 Dec 16451622361
30 Sep 16440552351
30 Jun 16439542380
31 Mar 16455552501
31 Dec 15456532531
30 Sep 15444122661
30 Jun 15400142222
31 Mar 15306-91612
31 Dec 14256-261234
30 Sep 14205-13657
30 Jun 14214-337110
31 Mar 14220-587512
31 Dec 13237-627814

Kwaliteitswinsten: 6242 has high quality earnings.

Groeiende winstmarge: 6242's current net profit margins (14.7%) are lower than last year (18.1%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 6242's earnings have grown by 13.4% per year over the past 5 years.

Versnelling van de groei: 6242's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: 6242 had negative earnings growth (-34.8%) over the past year, making it difficult to compare to the Personal Products industry average (-1%).

Rendement op eigen vermogen

Hoge ROE: 6242's Return on Equity (10.3%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y